NCT00501293
Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD
See it on ClinicalTrials.gov ↗163 people
25.2%
74.8%
41 womenmiddle line = equal numbers122 men
- Phase
- PHASE3
- Paid for by
- Noven Therapeutics
- Finished
- 2009-02
- Health conditions
- ADHD
- Who could join
- Anyone
- Ages
- 13 Years – 17 Years
- Average age
- mean 14.5 years
- Age 65+
- 0%
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- Age limit under 65
Older women were turned away, even though they often take this medicine.
“Maximum age: 17 Years.”
- No pregnant women
Women who were pregnant could not join.
“Female subject who is pregnant or lactating.”
- No breastfeeding moms
Women who were breastfeeding could not join.
“Female subject who is pregnant or lactating.”
- Had to use birth control
Women who couldn't or didn't want to use birth control were turned away.
“Females must have a negative urine pregnancy test at Entry and agree to use acceptable contraceptives throughout the study period and for 30 days the last dose of IP.”
Study titles and rules are shown in their original English.